Helena Marzo-Ortega

Jan 25, 2024 | nature.com | Stefan Siebert |Helena Marzo-Ortega

As in rheumatoid arthritis, achieving low disease activity or remission in psoriatic arthritis (PsA) remains a challenge and unmet need for many individuals. However, the complex pathogenesis, heterogeneity and varied tissue involvement in PsA mean that dedicated definitions and novel solutions are required for difficult-to-treat disease.

Nov 24, 2023 | ard.bmj.com | Helena Marzo-Ortega |Stephanie Harrison |György Nagy |Pedro Machado

Handling editor Josef S SmolenTwitter @LeedsTeamSpA, @LeedsBRC, @pedrommcmachado, @wabautistam, @LGossec, @StefanSiebert1Correction notice This article has been corrected since it published Online First. The acknowledgements statement has been added. Contributors HM-O: conceptualisation, survey development, wrote first draft of manuscript. SRH: survey development, data analysis. SS, GN, PMM and DGM: conceptualisation, survey development. SZA, RA-G, WB-M, LG, EL, PN, FPS and ERS: survey distribution.

Nov 14, 2023 | ard.bmj.com | Helena Marzo-Ortega |Stephanie Harrison |György Nagy |Pedro Machado

Handling editor Josef S SmolenTwitter @pedrommcmachado, @wabautistam, @LGossec, @StefanSiebert1Contributors HM-O: conceptualisation, survey development, wrote first draft of manuscript. SRH: survey development, data analysis. SS, GN, PMM and DGM: conceptualisation, survey development. SZA, RA-G, WB-M, LG, EL, PN, FPS and ERS: survey distribution. All authors contributed to write the manuscript and approved the final version.

Jul 13, 2023 | ard.bmj.com | Stefan Siebert |Helena Marzo-Ortega

http://orcid.org/0000-0002-1802-7311Stefan Siebert1, Helena Marzo-Ortega2 1 Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK 2 Leeds Institute of Rheumatic and Molecular Medicine, University of Leeds, Leeds, UK Correspondence to Professor Stefan Siebert, Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK; stefan.siebert{at}glasgow.ac.uk Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of...

Apr 14, 2023 | nature.com | Helena Marzo-Ortega |Stephanie Harrison

Among the wide range of drugs now available for the treatment of psoriatic arthritis, the best option for an individual patient remains unclear. Emerging real-world evidence from several Nordic registries suggests that differences exist in the response rates to different classes of biologic and targeted synthetic DMARDs in psoriatic arthritis. Refers to Glintborg, B. et al.